In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Vascular endothelial growth factor (VEGF) inhibitor / antagonist'
Please login to view adverse reactions.
- (2023): Dai S+, Front Pharmacol Jun (e-Collection) (17 cases)
- (2017): Oshima Y+, Circulation 135(8), 815-817 (pharmacovigilance / pharmacoepidemiology)
- (2021): Duco MR+, J Oncol Pharm Pract Jan, Online ahead of print60%
- (2015): Thompson LA+, J Oncol Pharm Pract 21(4), 258-67 [REVIEW]
- (2011): Escalante CP+, Cardiol Res Pract May (e-Collection) [REVIEW]
QT interval prolonged / QT prolongation
- (2015): Ghatalia P+, Br J Cancer 112(2), 296-305 [REVIEW]
Gastrointestinal adverse reaction
- (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]
Neutropenia (neutrophils decreased)
- (2019): Lv WW+, Medicine (Baltimore) 98(23), e1580625% [REVIEW]
Glaucoma (includes acute angle-closure glaucoma)
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
Intraocular pressure increased
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
Vitreous floaters / floaters / myodesopsia / myiodesopsia / muscae volitantes
- (2018): Jumper JM+, Clin Ophthalmol 12, 621
- Negative findings
- (2024): Barkmeier AJ, Ophthalmol Retina 8(8), 731-732 (no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept)
